These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 18827563)
1. Activity of lipoplatin in tumor and in normal cells in vitro. Arienti C; Tesei A; Ravaioli A; Ratta M; Carloni S; Mangianti S; Ulivi P; Nicoletti S; Amadori D; Zoli W Anticancer Drugs; 2008 Nov; 19(10):983-90. PubMed ID: 18827563 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity. Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355 [TBL] [Abstract][Full Text] [Related]
3. Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Boulikas T Expert Opin Investig Drugs; 2009 Aug; 18(8):1197-218. PubMed ID: 19604121 [TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Casagrande N; De Paoli M; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D Gynecol Oncol; 2013 Dec; 131(3):744-52. PubMed ID: 24029417 [TBL] [Abstract][Full Text] [Related]
5. Liposomal cisplatin: a new cisplatin formulation. Stathopoulos GP Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511 [TBL] [Abstract][Full Text] [Related]
6. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Boulikas T; Stathopoulos GP; Volakakis N; Vougiouka M Anticancer Res; 2005; 25(4):3031-9. PubMed ID: 16080562 [TBL] [Abstract][Full Text] [Related]
7. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Boulikas T Oncol Rep; 2004 Jul; 12(1):3-12. PubMed ID: 15201951 [TBL] [Abstract][Full Text] [Related]
8. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
9. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Casagrande N; Celegato M; Borghese C; Mongiat M; Colombatti A; Aldinucci D Clin Cancer Res; 2014 Nov; 20(21):5496-506. PubMed ID: 25231401 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study. Jehn CF; Boulikas T; Kourvetaris A; Possinger K; Lüftner D Anticancer Res; 2007; 27(1A):471-5. PubMed ID: 17352269 [TBL] [Abstract][Full Text] [Related]
11. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines]. Shang XB; Yu ZT; Tang P; Zhang XZ Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461 [TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
14. In vitro biochemical and pharmacological evaluation of a novel cytotoxic dinuclear platinum(II) complex with 3-amino-5-methyl-5-phenylhydantoin. Momekov GTs; Ugrinova I; Pasheva EA; Bakalova AG; Varbanov HP; Ferdinandov DV; Ivanov DS; Konstantinov SM Ann N Y Acad Sci; 2009 Aug; 1171():649-58. PubMed ID: 19723116 [TBL] [Abstract][Full Text] [Related]
15. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin. Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645 [TBL] [Abstract][Full Text] [Related]
16. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733 [TBL] [Abstract][Full Text] [Related]
17. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Song J; Shih IeM; Salani R; Chan DW; Zhang Z Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121 [TBL] [Abstract][Full Text] [Related]
18. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Zisowsky J; Koegel S; Leyers S; Devarakonda K; Kassack MU; Osmak M; Jaehde U Biochem Pharmacol; 2007 Jan; 73(2):298-307. PubMed ID: 17097621 [TBL] [Abstract][Full Text] [Related]
19. Low renal toxicity of lipoplatin compared to cisplatin in animals. Devarajan P; Tarabishi R; Mishra J; Ma Q; Kourvetaris A; Vougiouka M; Boulikas T Anticancer Res; 2004; 24(4):2193-200. PubMed ID: 15330160 [TBL] [Abstract][Full Text] [Related]
20. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme. Wang W; Liu G; Zheng J Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]